Abstract SPRASA (also referred to as SLLP1) is a protein identifi ed in the acrosome of human sperm and encoded by the gene SPACA3 . SPRASA is associated with sperm-oocyte recognition and binding, and may play a role in fertility. In order to determine whether variants in the SPACA3 gene are associated with human infertility, we undertook a genetic analysis of 102 infertile and 104 fertile couples. Three gene variants were identifi ed using PCR-based DNA sequencing; 1) an insertion of TGC within a quadruple trinucleotide (TGC) repeat region in the 5 ′ untranslated region (UTR) (g. -22TGC(4_5), 2) a guanine to adenosine transition at position 239 (c.239G Ͼ A) resulting in a non-synonymous amino acid substitution from cysteine to tyrosine (p.C80Y) at position 80 in the putative transmembrane region, and 3) a novel nucleotide variant (c.691G Ͼ C) located in the 3 ′ UTR. A functional effect of the g. -22TGC (4_5) was confi rmed by a luciferase expression assay, while the effects of the variants c.239G Ͼ A and c.691G Ͼ C were predicted using in silico analysis. Although the frequencies of these variants were not signifi cantly different between the infertile and fertile populations, we present evidence that the variants could affect the expression levels or function of SPRASA , thereby affecting a couple ' s fertility. Larger populations, especially individuals/couples with unexplained infertility, need to be screened for these variants to validate a relationship with fertility.
Introduction
The prevalence of infertility in Western countries such as New Zealand is estimated to be one in six couples, while one in eight couples require some form of medical assistance to achieve a pregnancy (HFEA, 2006) . Of these infertile cases, the precise cause of infertility for approximately 5 -15% of couples is unknown, and is referred to as unexplained infertility (Farquhar, 1998; Liu et al., 2007) . Standard investigations, including testing for ovulation, tubal patency and semen analysis are routine in these couples (Kamath & Bhattacharya, 2012) . The causes of unexplained infertility and infertility, in general, are likely to be heterogeneous, and may include endocrine, immunological, and genetic factors (Kamath & Bhattacharya, 2012; Pellicer et al., 1998) . It is also common to fi nd multiple potential causes of infertility in an infertile couple (Collins & Crosignani, 1992; Marrero & Ory, 1991; Quaas & Dokras, 2008) . SPRASA (also referred to as SLLP1) is a protein identifi ed in the acrosome of human sperm (Chi et al., 2004) . SPRASA is a member of the c-type lysozyme/ alpha-lactalbumin family (Chiu et al., 2004; Mandal et al., 2003) , and human SPRASA is encoded by a gene ( SPACA3 ) at chromosomal locus 17q11.2 (Mandal et al., 2003) . SPRASA is known to be the target for antisperm antibodies in some infertile men, and this protein has been shown to have roles in sperm -oocyte binding and early embryo development in murine, hamster, or bovine models (Chiu et al., 2004; Mandal et al., 2003; Zhang et al., 2005; A. Wagner, unpublished) . SPRASA expression was thought to be limited to the sperm/ testis and some tumour cells, but we have recently demonstrated it is also expressed by oocytes (A. Wagner, unpublished) . This pattern of gonad/gamete-specifi c expression also supports the concept that SPRASA has an important role in fertility (Herrero et al., 2005;  2 D. Prendergast et al. Human Fertility Mandal et al., 2003; Wagner, 2009 ). While we discovered SPRASA as the antigen for antisperm antibodies in some infertile men, the association of SPRASA with human infertility has not been investigated further. Because of SPRASA ' s putative importance in fertility, naturally occurring genetic variation that disrupts the function of SPRASA may have a role in human infertility. This study was undertaken to investigate whether genetic variants in the SPRASA-encoding SPACA3 gene are associated with infertility in humans.
Methods and materials

Ethics statement and study population
This study was approved by the Northern Regional Ethics Committee (Auckland, New Zealand). Blood samples obtained by venipuncture were collected following written informed consent from 102 infertile couples, (recruited through Fertility Associates, Auckland and Fertility Plus, Auckland; Supplementary Table I 
Mutation nomenclature
In accordance with current mutation nomenclature (den Dunnen & Antonarakis, 2001) , the adenosine of the ATG (initiator methionine codon) of SPACA3 is denoted nucleotide ϩ 1. Nucleotide numbers refer to GenBank accession number NM_173847.
Polymerase chain reaction
Genomic DNA was extracted from 5 to 10 mL of blood using the salting out protocol (Miller et al., 1988) . Eight sets of Polymerase chain reaction (PCR) primers were designed to fl ank exons and the putative promoter regions of SPACA3 (Supplementary Table III available online at: http//informahealthcare.com/doi/abs/10.31 09/14647273.2014.907506) . Genomic DNA (100ng) was amplifi ed using standard PCR conditions (Supplementary Tables III and IV available online at: http// informahealthcare.com/doi/abs/10.3109/14647273.2014. 907506). All PCR amplifi cations were performed in an iCycler (BioRad, Hempstead, UK). The PCR products were analysed using agarose gel electrophoresis, stained with ethidium bromide (10mg/ml; Sigma, Australia) and visualised under UV light.
DNA sequencing
The PCR products were purifi ed with the Roche High Pure PCR Product Purifi cation Kit (Roche, Basel, Switzerland) following the manufacturer ' s instructions. Sequencing reactions were performed using the ABI prism Big Dye Terminator Sequencing Kit v3.1 (ABI, Foster City, USA) following the manufacturer ' s instructions in a 20 μ L volume with approximately 5 ng per 100 bp of PCR product. All primers used in the sequencing reactions allowed for 100% coverage of the coding region for each sample. Sequencing reactions for exon four were supplemented with betaine at a fi nal concentration of 1.4M to assist sequencing through secondary structures (Haqqi et al., 2002) . The variants were confi rmed by sequence replication. Sequencing of the promoter variants was carried out in both directions using internal primers (Supplementary Table III Luciferase assays were performed using the Dual Luciferase Reporter Assay System (Promega, In vitro Technologies, Auckland) following the manufacturer ' s instructions. The promoter assays were normalised to Renilla luciferase activity from the co-transfected pRLTk vector. The means and standard error (SE) were calculated from identical transfections in triplicate from three independent experiments, and the two SPACA3 promoter variants were compared to the empty control plasmid transfected into the appropriate cell lines.
In silico analysis for function: variants g. -22TGC(4_5), c.239G Ͼ A and c.691G Ͼ C
The putative effects of the sequence variations on genetic association were predicted using the SHEsis programme (Shi & He, 2005) . The TESS (transcription element search software) prediction tool was used to determine whether the g. -22TGC(4_5) variant affected transcription factor binding (Schug & Overton, 1997) . The possible impact of the amino acid substitution p.C80Y (genetic variant c.239G Ͼ A) on the structure, function and expression of the SPRASA protein was tested using the three prediction tools; SIFT (sorts intolerant from tolerant) scores were classifi ed as intolerant (0.00 -0.05), potentially intolerant (0.051 -0.10), borderline (0.101 -0.20) or tolerant (0.201 -1.00) (Ng & Henikoff, 2003; Xi et al., 2004) ; PolyPhen II (polymorphism phenotyping), scores were designated probably damaging ( Ն 2.00), possibly damaging (1.50 -1.99), potentially damaging (1.25 -1.49), borderline (1.00 -1.24) or benign (0.00 -0.99) (Xi et al., 2004) ; Grantham matrix scores categorise codon replacement into classes of increasing chemical dissimilarity and are designated conservative (0 -50), moderately conservative (51 -100), moderately radical (101 -150) or radical ( Ն 151) (Grantham, 1974; Li et al., 1984; Rudd et al., 2005) . The potential effect on microRNA (miRNA) binding to the variant c.691G Ͼ C was analysed using the TargetScanHuman version 6.2 programme. TargetScan predicts biological targets of miRNAs by searching for the presence of conserved 8mer and 7mer sites that match the seed region of each miRNA (Lewis et al., 2005) , also identifi ed are sites with mismatches in the seed region that are compensated by conserved 3 ′ pairing (Friedman et al., 2009) . In mammals, predictions are ranked based on the predicted effi cacy of targeting as calculated using the context scores of the sites (Grimson et al., 2007) .
Sequence alignments
In order to obtain a measure of the level of evolutionary conservation of the variants, multiple sequence alignments of SPACA3 were performed as relevant for each variant using known orthologs with complete sequences in the programme Clustal W2. Thirteen higher primates possess known orthologs to human exon one containing the g. -22TGC(4_5) variant, 42 mammalian species possess known orthologs to human exon two containing the c.239G Ͼ A variant, and 23 mammalian species possess known orthologs to human exon fi ve containing the c.691G Ͼ C variant.
Statistical analysis
The chi-squared statistic was used to detect the HardyWeinberg equilibrium (HWE) for the three identifi ed sequence variations. The odds ratios and 95% confi dence interval were used to measure the association in the genotype and allele distribution of the three sequence variations between the infertile and fertile groups. The p values were estimated using chi-square test. Statistical analysis from the results of the luciferase assay comparing the promoter variants was determined using unpaired Student ' s T-test in the Graph Pad Prism 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58   59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116 4 D. Prendergast et al. Human Fertility 5.02 programme. All p values were two-tailed and considered signifi cant if p Ͻ 0.05.
Results
In order to investigate the population level variation in SPACA3 and to determine whether this variation is associated with infertility, 102 infertile couples ( n ϭ 204 individuals) and 104 fertile couples ( n ϭ 208 individuals) were analysed. Three sequence variants were identifi ed in this population; g. -22TGC(4_5), c.239G Ͼ A and c.691G Ͼ C (Figure 1 ; Table I ).
SPACA3 is well conserved in the cohort investigated; the minor allele frequencies for the variants were g. -22TGC(4_5) 0.12, c.239G Ͼ A 0.02 and c.691G Ͼ C 0.001. The variant c.691G Ͼ C was found at a population frequency of less than 0.01, and is thus defi ned as a mutation (den Dunnen & Antonarakis, 2001 ). There were a number of couples from the infertile and fertile cohorts who had a combination of multiple variants (Supplementary Table VII SPACA3 /SPRASA is highly evolutionarily conserved. A multiple sequence alignment of SPACA3 orthologs showed 100% conservation of the major variant in exons one and fi ve (Figure 2) . Analysis of SPACA3 orthologs in mammals showed that the guanosine/cytosine is conserved (100% conservation in 42 species; Figure 2) .
The fi rst variant in the SPACA3 gene consists of the insertion of an additional TGC within a quadruple trinucleotide TGC repeat region, g. -22TGC(4_5), and is situated in the 5 ' UTR of exon one (Figure 1 ). Allele frequencies for infertile and fertile individuals are shown in Table II In order to investigate the potential consequences of this SPACA3 variant on promoter function, we conducted luciferase reporter experiments using three cell lines. In vitro luciferase reporter assays comparing Promoter A (located fi ve-prime of exon one; major allele) and Promoter A g. -22TGC(4_5) variant (located fi veprime of exon one) found expression from Promoter A in the SPACA3 -expressing granulosa cell line KGN, with an approximately 1.4-fold increase in expression compared to the control. There was no expression above the normalisation-control from Promoter A in the SPACA3 -expressing seminoma cell line NCCIT or the non-SPACA3 -expressing embryonic kidney cell line HEK-293T. Promoter A g. -22TGC(4_5) variant did not induce expression above the normalisation-control in any cell line; there was a signifi cant difference between Promoter A and Promoter A g. -22TGC(4_5) variant expression in the reproductively relevant KGN cell line ( p ϭ 0.01; Figure 3 ). The function of Promoter B (located in intron one; invariant) was also assessed. Expression from Promoter B was found in the NNCIT (approximately 2.7-fold increase compared to the control) and KGN (approximately 5.6-fold increase compared to the control) cell lines. There was no expression above the normalisation-control from Promoter B in the HEK-293T cell line (Figure 3) .
The second variant, a guanosine to adenosine transition at position 239, c.239G Ͼ A, was identifi ed in exon two, which encodes the putative transmembrane region of the SPRASA protein (Figure 1 ). This transition occurred at the second residue of the codon and resulted in a non-synonymous amino acid substitution at codon position 80 from a cysteine to a tyrosine (p.C80Y). Allele frequencies for infertile and fertile individuals are shown in Table II To determine possible effects that the c.239G Ͼ A variant may have on the function of the transmembrane region, online prediction tools were used to examine the effect of the amino acid substitution p.C80Y. Bioinformatic analysis by SIFT (Ng & Henikoff, 2001; Xi et al., 2004) and PolyPhen II (Ramensky et al., 2002; Xi et al., 2004) programmes suggested that the substitution is not tolerated, and is predicted to be deleterious to protein (Abkevich et al., 2004; Grantham, 1974; Lee et al., 2008) . A third variant was identifi ed in exon fi ve and resulted in a guanosine to cytosine transversion at nucleotide position 691, c.691G Ͼ C (Figure 1 ; Table I ). This novel SNP occurred in the 3 ′ UTR in the heterozygous form in one individual, an infertile female (Table II) 
Discussion
Currently there is only limited knowledge about the specifi c proteins that are involved in human fertility, and how genetic variation in these proteins may affect fertility. In this study we investigated variations in the gene SPACA3 which encodes SPRASA, a little studied protein that has a role in sperm -oocyte binding (Chiu & Chamley, 2002; Chiu et al., 2004; Herrero et al., 2005; Mandal et al., 2003) and early embryonic development Human Fertility (A. Wagner, unpublished) . Levels of population genetic variation in SPACA3 were determined in a cohort of New Zealand males and females ( n ϭ 412). Limited variation was found in SPACA3 , suggesting that this gene may be well conserved, possibly because its potential role in fertilisation (Herrero et al., 2005; Mandal et al., 2003) means that variation would be detrimental to fertility. To explore whether variants in SPACA3 are associated with infertility in the New Zealand population, variation was investigated in infertile and fertile couples. Twenty-nine variants in SPACA3 have previously been recorded (NCBI SNP database http://www.ncbi.nlm. nih.gov/). In the New Zealand population, three variants were found. All variants were seen at higher frequencies in individuals belonging to infertile, compared to fertile, couples. However, none of these differences were statistically signifi cant. When investigating infertility, couples should be considered together (Campana et al., 1995) . Thus, analysis of couples found three variant combinations in the infertile couples only, suggesting that these variant combinations are possibly detrimental to fertility, although the variant combinations were not statistically associated with infertility. Given that infertility has many causes and is often multifactorial, it may be diffi cult to show an association with infertility in such a broad collection of individuals. The variants identifi ed may therefore be important in the pathogenesis of infertility in the affected individuals. Indeed, we determined that the variant encoding a cysteine to a tyrosine (p.C80Y) transition in the putative transmembrane region may affect the function of SPRASA. Further, the other two variants may affect the expression levels of SPRASA.
The functional activity of Promoter A (major allele) in the KGN cell line was abolished when Promoter A g. -22TGC(4_5) variant was transfected instead suggesting that the g. -22TGC(4_5) variant may reduce the expression of SPACA3 , and could lead to an effect on fertility. Further, the major allele at this locus is highly conserved, suggesting that any variation in this region may be deleterious. However, the g. -22TGC(4_5) variant was found in the homozygous state in three fertile couples, indicating that it does not lead to frank infertility in all individuals, and may have a subtle effect on fertility. A second promoter, Promoter B, is located in intron one. This promoter may allow the continuing expression of an isoform of SPRASA and, therefore, the continuation of some functions of SPRASA in fertility.
The c.239G Ͼ A variant results in a non-conservative change of a cysteine to tyrosine and is located in the putative transmembrane region of SPRASA. In silico analyses suggest that this substitution is deleterious to the function of SPRASA, and analysis of SPACA3 orthologs confi rms that the cysteine is highly conserved, further indicating that it may be crucial for protein function. The c.239G Ͼ A variant was only seen in the homozygous state in a single infertile female, which may indicate an effect on fertility of non-functional SPRASA in this individual. The allele frequency of the c.239G Ͼ A variant in the New Zealand population (0.02) is similar to the European and Asian frequencies (0.03 and 0.01, respectively; refer to cluster reports ss227519113, ss23645285, and ss237222685 on dpSNP http://www. ncbi.nlm.nih.gov/snp), indicating the potential of this variant to affect fertility in multiple populations.
The heterozygous variant c.691G Ͼ C was identifi ed in a single female with unexplained infertility. The major variant at this locus is conserved across all known SPACA3 orthologs, indicating its importance to the functioning of SPRASA. This variant is located within the seed region for hs-miR873, a miRNA Pasten-Hidalgo et al., 2008 ) that can specify posttranscriptional repression by transcript destabilisation/translational repression (Friedman et al., 2009) . The identifi cation of hs-miR873 and the conservation of this region suggest that this locus may be important in the regulation of SPACA3 by affecting the stability and/or translation of the mRNA, thereby affecting levels of the SPRASA protein.
Summary
In this investigation, we have determined that SPACA3 has low levels of variation in our study population. Three variants were detected; although none were statistically associated with infertility; this is not a surprising fi nding, given the multifactorial nature of infertility. Furthermore, because infertility has multiple causes, the explanation of an individual ' s infertility may not be associated with infertility when examined on a population basis. All three of the variants were found at higher frequencies in the infertile cohort and one of the variants was only found in the homozygous state in an infertile individual, suggesting that this could be associated with the pathogenesis of infertility in some individuals/ couples. Two of the variants may affect the expression levels of SPACA3, and the other variant may affect the function of SPRASA. Results from multiple models indicate that SPRASA is important in fertility (Chiu et al., 2004; Mandal et al., 2003; Zhang et al., 2005; A. Wagner, unpublished) , and thus variants that affect SPRASA ' s function or expression levels may compromise fertility for some couples. Further functional studies are required to determine whether the presence of these variants has a role in infertility. Due to non-specifi c primer binding, exon two, four and the promoter were amplifi ed by Touchdown PCR 70 ° C -60 ° C. 1 The promoter amplicons followed the same Touchdown PCR protocol as exon two and four with the exception that the time for the fi rst 20 cycles was extended to one minute. 
